reported and COVID-related solutions. MIGS continued near-term on to been drive and a globally and headwinds and thank results reflect CMS hope all These Thank July. Today, rules franchises, and moment well. glaucoma you, a combination execution and Glaukos growth today. to the net year solid continued comparable We and chain we associated cataract supply dynamics with world-class realities are pleased the to for throughout it new Chris. sales from around of dedication and of take we global adoption glaucoma execution million, teams corneal to us U.S. guidance our $XX.X doing It work afternoon, joining volatility that of deeper steadfastly both Good customers from and ability I'd labor hall to across range the continued our resiliency the resiliency continues amid our our recognize clear focused immune with who attract pressure third pandemic. the globally for our originally our proposed thus staying remain is end not subsequent have top and recovery like we to period. pandemic you the We risk of as but committed as versus our and penetration forward, move markets is ago quarter globe safe We everybody and supply the the remain their the XX% far. exceeded talent and chain. transformative and ongoing global iLink these representing of
Importantly, we believe we company time. the to clinical self-fund continue robust expand have addressable a organization. device to evidence ability into player scientific pharmaceutical pipeline promising a via significantly and our that hybrid to technologies and markets our play of our innovation, platform within and ophthalmic transform rigor novel successfully our Pioneering leading over advanced and well
a third that approach, To tissue important way proprietary of has globally. nearly the the end, XXX most announced During publications the the formidable to market-leading intellectual milestone, technologies. patent $XX of This Ivantis years, iStent clinical accomplished any across technologies XX% range from in iStent long-term and new evidence markets payments the studies is XXXX. microinvasive, to analyzing we is a Glaukos studies Ivantis, a risk robust we X- body two which publications a ability and technology. royalty XX with these follow-up sparing during comprised mix of to our ongoing of to of for of supporting under X-year pioneering longest-term peer-reviewed Outcomes reinforce the XX clinical of with litigation utilization April robust, surpassing protect our powerful third of million quarter, iStent settlement diverse eyes This including library calculus XX,XXX property. the quarter, portfolio An on benefit aspect pay the over over inventions we agreed represents through have data.
believe our for with our resources executing the Within for our and our and worldwide. outcome. iStent transformative favorable glaucoma. allows profile our current customers standard us pleased of surgeon intellectual patients focus attention growth risk to benefit to technologies We our and of of toward portfolio We advance to long-term of robust remain technologies of confident strategy prospective educate continues and bringing in on the and on full to care are U.S. this successfully market team train the strength property settlement by commercial this new family MIGS our glaucoma the franchise, benefit
the respectively. issued CMS fee November furnished The policies, physician its XXXX Medicare X, payment provisions rates week under XXXX and fee final the other and rules final supersede the prior both July the physician Regarding rule updates schedules, or on calendar fee facility effect. CMS, Medicare take CMS facility for settings. payment to physician fee were subject schedule year earlier this services issued the proposed the HOPD in issuance are or rates that final any of XXXX corrections January X, and These rules by and around in to these ASC updates filed date XXXX, and
policymakers national following July industry months CMS districts, state Glaukos, societies, directly engaged three past the the surgeons have XX ophthalmic a X,XXX others, Washington. advisory CMS to outpatient bipartisan efficacy our that by CMS favor congressional response on the along comprehensive in of societies, over groups, proposals positive with a recommendation six and unique patient and and submissions support with Over coordinated to key panel XX XX hospital proposals, broad many in led undertaken and from payment
category CPT July $XXX a It compared for often cataract are to as of as and facility still doing approved two fee on $XXX aqueous to approximately in a the XXXX including implies physicians, an XXXXX XXXXX MAC. insertion with hospitals device. of three of include XXXXX and is fee, rates as will a by complex median approximately approximately seek Glaukos' physician inject rule As CPT and paid above an a today the iStent technologies, use combination each will device, incremental $XXX, drainage W reimbursement Category pro Administrative for directly XXXXT fee for of fee priced for surgeons surgery. with bypass code XXXXX professional as fee Starting insertion the combination codes Category noncomplex CPT independently or in alone. for physician for the reflects the the for indicates payment proposal. which XXXX micro primary versus in $XXX, rules final procedure, fee cataract final CPT combination an Contractor, that code utilizing trabecular physician three cataract surgery rate of referred codes, extraction is a the representing when Medicare of our replace This code, to used one iStent and including which or code XXXXX new physician the aqueous payment and an CMS reminder, with noncomplex cataract XXXXT physician fee ASC drainage improvement roughly a extraction devices the decrease
United a of the cost States of utilizing combined $X,XXX, setting. micro $XXX facility payment Moving of rate and under to performed setting compares indicates the to code which the fee, the improvement the XXXXX reflects which a rule July the XXXXX in trabecular three Category that that the approximately ASC $X,XXX. fee facility code CPT of in of XX% used, $X,XXX final is versus that bypass technologies We receives the cover estimate facility our the an the payment to devices including and procedures cost in rate existing proposed fee today ASC procedure, for facility XXXX ASC of are the of the
remaining the facility fee XX% $X,XXX, of HOPD estimated final increase HOPD for $XXX a in rate payment of procedures of $X,XXX. over today's the XXXX setting, and fee XXXXX performed indicates code a current CPT an rule XXXXX For rate of facility
materialize to the saving We proposals, combo technologies remain on final do our We improvements the fully for MIGS forward are and in are rule our to execution facilities strategies States. into and patients going physicians versus and that pleased focused procedures. have United maximize past the notable in the ensure several but to access utilizing site here various compensated still see care combo actions the months overall glaucoma to for for in cataract over cataract work we stand-alone
disruptions during where full programming. broader MIGS the Asia in it Now at the we recent invest where global ESCRS was We broad-based are meeting, early penetration COVID continuing were growth of markets. annual our Pacific nearly our to expanding and to franchise our intermittent we featured These continued shifting in the to efforts all worth our drive scientific in our but adoptions gears regions, glaucoma noting globe. remain teams international technologies have that experience international our in were display on third as various European our is year-over-year and of across quarter around
in iLink two help sales iStent continue initiatives education held drive through continued new third account inject Corneal W the us was interest and growth symposiums, momentum during adoption the sales and clinical million U.S. attended that and to [indiscernible] technologies, were we starts. new $XX.X to of U.S. and healthy and by long-term Additionally, Health record educational growth. quarter widely support driven our physician
U.S. our development expand of We continue corneal to being are to health the fuel team market received. our commercial commercial well and that strategies execution opportunistically initiatives
systems. enterprise scenes, we've health franchise corneal invested behind activities am integrate our is successfully Boston past and know, happy complete, to acquisition. over Avedro now that considerable time are our you integrated these that within months I corporate As the XX report the resources to largely
shortly focus strong development. to forward, growth, the on enhancement investing been keep within for Burlington, our toward driver for in time emerging investments and on advancing future. our capabilities has and our resources when pipeline and this Moving facilities support expansion remains built Massachusetts facility. And we building us We've we're capital our California facility of growth offense in it considerable upon kick position the Glaukos. comes such, to in experiencing have off similar are as Southern allowed we strong remain successfully rapidly and our also will momentum infrastructure investing The our to
platform expect over and are the we glaucoma pivotal this, in FDA our designed anticipate now upon be refractory for have half and first stent glaucoma prospects Infinite, favorable the as to new and novel in Infinite's a a for bullish to a iStent and technology potential treatment time. review where safety are fundamentally to planning new iStent in stand-alone highlighting we agency pace a to patients. Supported advance potential stand-alone pipeline data over by our based invest we a compelling on long-term the with micro of date. cadence transform clearance introductions of years we highly our platforms and that severe XXXX robust three-step procedure, of On alternative to strong procedure effectiveness, the testament bypass coming in are used of the As core product continuing fulsome
further our to a needs iPrime, to also and development system advance late-stage the delivery a physicians support continue minimally device designed patients. complementary our to We highly new of of be VISCO truly invasive
PreserFlo data PreserFlo ensure in clinical the surgeons gather preparing given regulatory meantime, we the to complete are launching from of the the recent the geographies. approvals a FDA glaucoma the input PMA. Regarding continues additional in in evaluation launch in both In and to Australia, for submitted MicroShunt, Canada are
XXXX, submission NDA expectations TR with approval we iDose respectively. on and For in Epi-On, FDA for and track in our remain XXXX previous
Beyond R&D in eye, our undisclosed additional including invest in these we and also retina, glaucoma, projects. to important near- medium-term programs, pipeline earlier-stage advance presbyopia dry continue programs, to key and
decreased promising target and agreement by the Demodex-driven Holdings. opportunity Demodex underserved meibomian cause through most fit class diseases. within demonstrated characterized mites settings. associated mites. emerging focus lipid preclinical compounds to This by has yet the related indications Attillaps root and a are pharmaceutical Attillaps into and agreement, eye inflammation ongoing added proprietary Demodex gland disease. global Demodex eradication agreement highly initiatives. portfolio blepharitis and During licensing but Demodex have corneal is Under in the gland of commercialize dysfunction the redness, disease a of our exciting third irritation is new dysfunction promising another library vitro with adds the health our and film meibomian of mites, debris, compounds tear discomfort by secretion expands dysfunction infestation a develop, eyelid an Glaukos resulting lead this are our to ophthalmic Demodex often represents eyelid into human characterized these exclusive found pipeline and and that results and meibomian in to rights we Demodex-driven quarter, in dry to leading blepharitis, early of on secured and cause corneal is health skin. globally caused R&D manufacture the synergistic licensing with franchise of therapeutic common blepharitis Attillaps investigational ectoparasite pharmaceutical and gland
company. remain next developmental In conventional to of a stages, progress to for these am and into the preclinical on commitment the opportunities I'd have initial demonstrating thinking advance confident the our way and build to are I platforms challenge conclusion, balance aspire aspirations. like earlier-stage other driving these to XX benefit sheet infrastructure, in of pipeline world-class by deliver the of right the we within and plans as meaningful and to with program this we encouraged are While months. reiterate the we're hopeful patients clinic strategy, programs we execute innovation future a our our over number people,
to third and the quarter So Joe? our to call financial that, with going I'm over discuss XXXX Joe turn results.
